[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369936-105":59,"doc-detail-369936-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","li-fraumeni-syndrome-in-the-uk-clinical-characteristics-and-outcomes-of-tp53-carriers","Li Fraumeni syndrome in the UK - clinical characteristics and outcomes of TP53 carriers","","Li Fraumeni syndrome (LFS) is a rare autosomal dominant genetic disorder with a high lifetime cancer risk driven by pathogenic or likely pathogenic TP53 germline variants. A retrospective UK dataset analyzed 57 patients from 41 families diagnosed between 1996 and 2021, describing observed cancer types, age at diagnosis, and treatment patterns before and after TP53 testing. Predictive testing identified unaffected carriers, while diagnostic testing revealed multiple cancers, mainly breast cancers and sarcomas, early-stage presentation, recurrence, and substantial cancer-related mortality.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/li-fraumeni-syndrome-in-the-uk-clinical-characteristics-and-outcomes-of-tp53-carriers/369936/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/li-fraumeni-syndrome-in-the-uk-clinical-characteristics-and-outcomes-of-tp53-carriers/369936.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the study on TP53 carriers with Li Fraumeni syndrome in the UK?","Question",{"text":112,"@type":113},"To describe clinical characteristics and cancer outcomes in TP53 carriers with Li Fraumeni syndrome, including cancer types, age at diagnosis, treatments, and results across predictive versus diagnostic testing groups.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients and families were included in the retrospective dataset?",{"text":117,"@type":113},"The study included 57 patients from 41 families diagnosed with Li Fraumeni syndrome between 1996 and 2021 and managed at a single UK cancer institution.",{"name":119,"@type":110,"acceptedAnswer":120},"What cancers were most commonly observed, and when were diagnoses most likely to occur?",{"text":121,"@type":113},"Most diagnoses involved breast cancers and sarcomas, and individuals were most likely to be diagnosed with Li Fraumeni syndrome between ages 30 and 40 years.",{"name":123,"@type":110,"acceptedAnswer":124},"What conclusions are drawn about surveillance and future research needs?",{"text":125,"@type":113},"The study concludes that individuals with Li Fraumeni syndrome face high risks of cancer, recurrence, and death, and it calls for larger multicentric international studies to better define patterns by TP53 variant and guide more targeted surveillance.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},369936,1790312661,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","ORIGINAL ARTICLE  \nLi Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriers  \nE. Finn1 ∗, S. Sardo Infirri1, C. S. Clarke2, C. Bunce1, J. Y. Weng2, R. W. Lee1 , 3 , 4, Z. Kemp1 , 3, T. P. McVeigh1, R. Eeles1 , 3 &  \nA. George1 , 3  \n1Royal Marsden Hospital NHS Foundation Trust, London; 2Research Department of Primary Care and Population Health, University College London, London; 3The Institute of Cancer Research, London; 4National Heart and Lung Institute, Imperial College London, London, UK  \nAvailable online 20 August 2025  \nBackground: Li Fraumeni syndrome (LFS), a rare genetic condition, poses a significant health impact due to the ∼75% - 90% lifetime risk of developing cancer in affected individuals. Due to the rarity of this disease, little is known about the outcomes, clinical characteristics, and treatments of cancer for patients with LFS.  \nPatients and methods: We present a retrospective dataset of 57 patients from 41 families diagnosed with LFS between 1996 and 2021, with or without a concurrent cancer diagnosis, who were managed at a single cancer institution in the UK. We present the cancer types that were observed in this group, the age at cancer diagnosis, and treatment modalities for those affected with cancer, either before or after having a TP53 test to establish their LFS diagnosis.  \nResults: A total of 24 individuals underwent predictive testing, of which 13 were not diagnosed with cancer during the observation period. The other 33 individuals underwent diagnostic testing and had at least one cancer diagnosis each. Overall, there were 92 distinct cancer diagnoses in 44 participants, the majority being breast cancers and sarcomas. Patients were most likely to be diagnosed with LFS between the ages of 30 and 40 years. Some 75% of all cancer diagnoses were diagnosed at an early stage [TNM (tumour—node—metastasis) stage 0-2], and 19% had a recurrence, despite the early diagnosis. In total, 42% of individuals with LFS died as a result of a cancer diagnosis in our dataset, but the overall survival could not be calculated due to the short follow-up period (median 6 years, IQR 2-11 years) .  \nConclusions: Individuals with LFS have a high risk of cancer, cancer recurrence, and death. Larger multicentric international studies focusing on developing cohorts of specific diseases are needed to better understand disease patterns related to different pathogenic TP53 variants and inform which patients with LFS may need a more targeted and aggressive surveillance protocol.  \nKey words: Li Fraumeni syndrome, breast cancer, sarcoma, early diagnosis, screening, electronic patient record, service evaluation  \nBACKGROUND  \nLi Fraumeni syndrome (LFS) is a rare autosomal dominant genetic condition that predisposes an individual to develop (often multiple) cancers throughout their lifetime. People with LFS are born with a pathogenic (P) or likely pathogenic (LP) germline alteration in the TP53 gene, either inherited from one  \nof their parents or arising de novo during embryogenesis.1  \nIt is estimated that LFS occurs in ∼ 1 in 5000 to 1 in 20 000 people worldwide. In the UK, LFS could affect >400-600 individuals, including children.2,3 More than 90% of women and  \n*Correspondence to: Dr Elena Finn, 203 Fulham Road, London, SW3 6JJ, UK. Tel: +44-020-7352-8171  \n[E-mail:](E-mail: elena.finn@nhs.net)[ elena.finn@nhs.net](E-mail: elena.finn@nhs.net) (E. Finn).  \n2059-7029/© 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \naround 75% of men with an inherited P/LP variant in the TP53 gene will develop cancer during their lifetime.4-6 The risk of cancer imparted by TP53 mutations is evident at an early age, with women in LFS families who carry such mutations having a cumulative 49% risk of devel","cbCaibu36A7gYYCW","https://ap.wps.com/l/cbCaibu36A7gYYCW","pdf",613557,"English","# Background\n# Patients and methods\n# Results\n# Conclusions\n# Key words","[{\"question\":\"What is the main purpose of the study on TP53 carriers with Li Fraumeni syndrome in the UK?\",\"answer\":\"To describe clinical characteristics and cancer outcomes in TP53 carriers with Li Fraumeni syndrome, including cancer types, age at diagnosis, treatments, and results across predictive versus diagnostic testing groups.\"},{\"question\":\"How many patients and families were included in the retrospective dataset?\",\"answer\":\"The study included 57 patients from 41 families diagnosed with Li Fraumeni syndrome between 1996 and 2021 and managed at a single UK cancer institution.\"},{\"question\":\"What cancers were most commonly observed, and when were diagnoses most likely to occur?\",\"answer\":\"Most diagnoses involved breast cancers and sarcomas, and individuals were most likely to be diagnosed with Li Fraumeni syndrome between ages 30 and 40 years.\"},{\"question\":\"What conclusions are drawn about surveillance and future research needs?\",\"answer\":\"The study concludes that individuals with Li Fraumeni syndrome face high risks of cancer, recurrence, and death, and it calls for larger multicentric international studies to better define patterns by TP53 variant and guide more targeted surveillance.\"}]","Li Fraumeni syndrome in the UK - clinical characteristics and outcomes of TP53 carriers | PDF",1790185284,25,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ea044496517623f30ae8821c8e49719.webp",983,1269,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b4affb1c8275ca4e3bab685939dd93c.webp",982,1268,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bcc988722bd6812ccd26b4a414a3134.webp",981,1266,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/815b134bee749fcc69d42f78a1b180bf.webp",980,1265]